The Company has entered into Share Purchase Agreement with Remidex Pharma Private Limited
M&A
● No Immediate Change
MEDIUM RISK
📅 Filed on BSE: 13 Mar 2026, 08:11 PM IST · BSE ID: 2192a781-6db7-424f-95f6-9d6bf0fff594
View Original BSE Filing (PDF)
🤖 AI Summary
- Jubilant Ingrevia Limited has signed a Share Purchase Agreement to acquire 100% equity stake in Remidex Pharma Private Limited for Rs. 16.5 Cr in cash, subject to customary closing conditions. Remidex, incorporated June 15, 1981, manufactures multivitamin premixes and nutraceuticals from its Bangalore facility. The acquisition is expected to close within 30 days. Remidex recorded turnover of Rs. 24.27 Cr in FY 24-25, down from Rs. 31.15 Cr in FY 23-24. The deal is not a related-party transaction. Jubilant says this expands its human nutrition portfolio, building on its existing vitamins leadership.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition price (cash consideration)
Rs. 16.5 Cr
Remidex turnover FY 24-25
Rs. 24.27 Cr
-22.2%
Remidex turnover FY 23-24
Rs. 31.15 Cr
Remidex turnover FY 22-23
Rs. 30.51 Cr
Stake acquired
100% Equity Shares
Expected deal closure timeline
30 days
👥 What This Means For Shareholders
✅
Action Required
No action required — informational filing only. Monitor for post-closing integration updates and impact on consolidated financial results.
👤
Who Is Affected
All existing shareholders are equally affected as this is a cash-funded acquisition with no equity dilution or share issuance. Future consolidated earnings will include Remidex's contribution post-closing.
🔍
Management Signal
Acquisition signals Jubilant's intent to diversify within nutrition — moving beyond vitamins into higher-value premix manufacturing to capture fuller value chain.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Deal closure announcement and confirmation of final purchase price within 30 days
Remidex integration roadmap and contribution to FY 25-26 consolidated results
Management commentary on premix segment margins and customer base synergies
MEDIUM RISK
Target revenue declined 22% YoY; acquisition completion hinges on customary closing conditions. Integration execution and margin accretion timing unclear from filing.
💡 Investor Takeaway
Jubilant Ingrevia is acquiring Remidex Pharma's 100% stake for Rs. 16.5 Cr cash to enter premixes segment. Target is profitable but saw 22% revenue decline YoY to Rs. 24.27 Cr. Deal expected to close in 30 days with no related-party conflict.
⚖️ Strengths & Concerns
✅ Positives
- Remidex is established player with 45-year track record since 1981 incorporation and WHO-GMP, FSSC, FSSAI certifications.
- Deal structure is cash consideration only at Rs. 16.5 Cr with 30-day closure timeline and no regulatory approvals needed.
⚠️ Concerns
- Remidex turnover declined 22.2% YoY to Rs. 24.27 Cr in FY 24-25 from Rs. 31.15 Cr prior year.
- Acquisition price not disclosed relative to target's current or normalized earnings — no valuation basis provided.